oHCM Webinar Series: A Multidisciplinary Approach to the Diagnosis of Obstructive Hypertrophic Cardiomyopathy (RECORDING)

Wednesday, July 30, 2025, 12:00 AM - Saturday, July 29, 2028, 11:59 PM, On Demand

Explore the latest in obstructive hypertrophic cardiomyopathy (oHCM) diagnosis and treatment. This educational activity helps clinicians improve recognition and management of oHCM to enhance patient outcomes. Learn about pathophysiology, novel mechanisms of action, clinical trials, and real-world data. Gain practical tools to improve diagnostic accuracy and deliver timely care. Stay at the forefront of oHCM advances and elevate your practice.

Release Date:  July 30, 2025
Expiration Date: July 29, 2028
Estimated Time to Complete: 1.5 hours
Registration Fee:  FREE 

*Originally recorded on June 13, 2025
Click Begin to access the video.

AMA PRA Category 1 Credits™ (1.50 hours), AAPA Category 1 CME credits (1.50 hours), ANCC Contact Hours (1.50 hours), Non-Physician Participation Credit (1.50 hours)

1. Identify the latest diagnostic tools and strategies for the early detection and intervention of obstructive hypertrophic cardiomyopathy (oHCM) to improve patient. outcomes.
2. Integrate newly available resources and evidence-based strategies into clinical practice to enhance the early identification and management of oHCM.
3. Apply emerging evidence-based guidelines and best practices in the management of obstructive hypertrophic cardiomyopathy (oHCM).

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 
Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Enduring Material for a maximum of 1.50 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Nurses Credentialing Center (ANCC) 
Stanford Medicine designates this Enduring Material activity for a maximum of 1.5 ANCC contact hours.  

American Academy of Physician Associates (AAPA) - Enduring Materials
Stanford Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This Enduring Material activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 07/29/28. PAs should only claim credit commensurate with the extent of their participation. 

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require visual, auditory, cognitive, or mobility accommodations, please contact the CME office.

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: https://laneguides.stanford.edu/multicultural-health

References and Additional Resources
Amano, Y., Kitamura, M., Takano, H., Yanagisawa, F., Tachi, M., Suzuki, Y., Kumita, S., & Takayama, M. (2018). Cardiac MR Imaging of Hypertrophic Cardiomyopathy: Techniques, Findings, and Clinical Relevance. Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 17(2), 120–131. https://doi.org/10.2463/mrms.rev.2017-0145

Camaioni, C., Knott, K. D., Augusto, J. B., Seraphim, A., Rosmini, S., Ricci, F., Boubertakh, R., Xue, H., Hughes, R., Captur, G., Lopes, L. R., Brown, L. A. E., Manisty, C., Petersen, S. E., Plein, S., Kellman, P., Mohiddin, S. A., & Moon, J. C. (2020). Inline perfusion mapping provides insights into the disease mechanism in hypertrophic cardiomyopathy. Heart (British Cardiac Society), 106(11), 824–829. https://doi.org/10.1136/heartjnl-2019-315848

Chan, R. H., Maron, B. J., Olivotto, I., Pencina, M. J., Assenza, G. E., Haas, T., Lesser, J. R., Gruner, C., Crean, A. M., Rakowski, H., Udelson, J. E., Rowin, E., Lombardi, M., Cecchi, F., Tomberli, B., Spirito, P., Formisano, F., Biagini, E., Rapezzi, C., De Cecco, C. N., … Maron, M. S. (2014). Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation, 130(6), 484–495. https://doi.org/10.1161/CIRCULATIONAHA.113.007094

EchoSAP - American College of Cardiology. (2024). American College of Cardiology. https://www.acc.org/Education-and-Meetings/Products-and-Resources/EchoSAP

Gati, S., Sharma, S., & Pennell, D. (2018). The Role of Cardiovascular Magnetic Resonance Imaging in the Assessment of Highly Trained Athletes. JACC. Cardiovascular imaging, 11(2 Pt 1), 247–259. https://doi.org/10.1016/j.jcmg.2017.11.016

Ghazal S. N. (2017). Valsalva maneuver in echocardiography. Journal of echocardiography, 15(1), 1–5. https://doi.org/10.1007/s12574-016-0310-8

Green, J. J., Berger, J. S., Kramer, C. M., & Salerno, M. (2012). Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC. Cardiovascular imaging, 5(4), 370–377. https://doi.org/10.1016/j.jcmg.2011.11.021

Hughes, R. K., Knott, K. D., Malcolmson, J., Augusto, J. B., Mohiddin, S. A., Kellman, P., Moon, J. C., & Captur, G. (2020). Apical Hypertrophic Cardiomyopathy: The Variant Less Known. Journal of the American Heart Association, 9(5), e015294. https://doi.org/10.1161/JAHA.119.015294

Kramer, C. M., Barkhausen, J., Bucciarelli-Ducci, C., Flamm, S. D., Kim, R. J., & Nagel, E. (2020). Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 22(1), 17. https://doi.org/10.1186/s12968-020-00607-1

Mandes, L., Rosca, M., Ciuperca, D., & Popescu, B. A. (2020). The role of echocardiography for diagnosis and prognostic stratification in hypertrophic cardiomyopathy. Journal of echocardiography, 18(3), 137–148. https://doi.org/10.1007/s12574-020-00467-9

Maron, M. S., Maron, B. J., Harrigan, C., Buros, J., Gibson, C. M., Olivotto, I., Biller, L., Lesser, J. R., Udelson, J. E., Manning, W. J., & Appelbaum, E. (2009). Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. Journal of the American College of Cardiology, 54(3), 220–228. https://doi.org/10.1016/j.jacc.2009.05.006

Mitchell, C. C., Frye, C., Jankowski, M., Symanski, J., Lester, S. J., Woo, A., Gilliland, Y., Dragulescu, A., Abraham, T., Desai, M., Martinez, M. W., Nagueh, S. F., & Phelan, D. (2023). A Practical Approach to Echocardiographic Imaging in Patients With Hypertrophic Cardiomyopathy. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 36(9), 913–932. https://doi.org/10.1016/j.echo.2023.04.020

Nagueh, S. F., Phelan, D., Abraham, T., Armour, A., Desai, M. Y., Dragulescu, A., Gilliland, Y., Lester, S. J., Maldonado, Y., Mohiddin, S., Nieman, K., Sperry, B. W., & Woo, A. (2022). Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 35(6), 533–569. https://doi.org/10.1016/j.echo.2022.03.012

Neubauer, S., Kolm, P., Ho, C. Y., Kwong, R. Y., Desai, M. Y., Dolman, S. F., Appelbaum, E., Desvigne-Nickens, P., DiMarco, J. P., Friedrich, M. G., Geller, N., Harper, A. R., Jarolim,

P., Jerosch-Herold, M., Kim, D. Y., Maron, M. S., Schulz-Menger, J., Piechnik, S. K., Thomson, K., Zhang, C., … HCMR Investigators (2019). Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. Journal of the American College of Cardiology, 74(19), 2333–2345. https://doi.org/10.1016/j.jacc.2019.08.1057

Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., Joglar, J. A., Khan, S. S., Kim, J. J., Kittleson, M. M., Krittanawong, C., Martinez, M. W., Mital, S., Naidu, S. S., Saberi, S., Semsarian, C., … Peer Review Committee Members (2024). 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 149(23), e1239–e1311. https://doi.org/10.1161/CIR.0000000000001250

Robinson, A. A., Chow, K., & Salerno, M. (2019). Myocardial T1 and ECV Measurement: Underlying Concepts and Technical Considerations. JACC. Cardiovascular imaging, 12(11 Pt 2), 2332–2344. https://doi.org/10.1016/j.jcmg.2019.06.031

Rowin, E. J., & Maron, M. S. (2016). The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy. Arrhythmia & electrophysiology review, 5(3), 197–202. https://doi.org/10.15420/aer.2016:13:3

Swoboda, P. P., McDiarmid, A. K., Erhayiem, B., Broadbent, D. A., Dobson, L. E., Garg, P., Ferguson, C., Page, S. P., Greenwood, J. P., & Plein, S. (2016). Assessing Myocardial Extracellular Volume by T1 Mapping to Distinguish Hypertrophic Cardiomyopathy From Athlete's Heart. Journal of the American College of Cardiology, 67(18), 2189–2190. https://doi.org/10.1016/j.jacc.2016.02.054

Guazzi M. (2014). Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. Circulation. Heart failure, 7(2), 367–377. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000823

Russell, S. D., McNeer, F. R., & Higginbotham, M. B. (1998). Exertional dyspnea in heart failure: a symptom unrelated to pulmonary function at rest or during exercise. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group. Am Heart J, 135(3), 398–405. https://doi.org/10.1016/s0002-8703(98)70314-x

Saberi, S., Wheeler, M., Bragg-Gresham, J., Hornsby, W., Agarwal, P. P., Attili, A., Concannon, M., Dries, A. M., Shmargad, Y., Salisbury, H., Kumar, S., Herrera, J. J., Myers, J., Helms, A. S., Ashley, E. A., & Day, S. M. (2017). Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JAMA, 317(13), 1349–1357. https://doi.org/10.1001/jama.2017.2503

Borrelli, F., Losi, M. A., Canciello, G., Todde, G., Perillo, E. F., Ordine, L., Frisso, G., Esposito, G., & Lombardi, R. (2023). Sarcomeric versus Non-Sarcomeric HCM. Cardiogenetics, 13(2), 92-105. https://doi.org/10.3390/cardiogenetics13020009

Faienza, M. F., Meliota, G., Mentino, D., Ficarella, R., Gentile, M., Vairo, U., & D'amato, G. (2024). Cardiac Phenotype and Gene Mutations in RASopathies. Genes, 15(8), 1015. https://doi.org/10.3390/genes15081015

Hathaway, J., Heliö, K., Saarinen, I., Tallila, J., Seppälä, E. H., Tuupanen, S., Turpeinen, H., Kangas-Kontio, T., Schleit, J., Tommiska, J., Kytölä, V., Valori, M., Muona, M., Sistonen, J., Gentile, M., Salmenperä, P., Myllykangas, S., Paananen, J., Alastalo, T. P., Heliö, T., … Koskenvuo, J. (2021). Diagnostic yield of genetic testing in a heterogeneous cohort of 1376 HCM patients. BMC cardiovascular disorders, 21(1), 126. https://doi.org/10.1186/s12872-021-01927-5

Hespe, S., Waddell, A., Asatryan, B., Owens, E., Thaxton, C., Adduru, M. L., Anderson, K., Brown, E. E., Hoffman-Andrews, L., Jordan, E., Josephs, K., Mayers, M., Peters, S., Stafford, F., Bagnall, R. D., Bronicki, L., Callewaert, B., Chahal, C. A. A., James, C. A., Jarinova, O., … Ingles, J. (2025). Genes Associated With Hypertrophic Cardiomyopathy: A Reappraisal by the ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel. Journal of the American College of Cardiology, 85(7), 727–740. https://doi.org/10.1016/j.jacc.2024.12.010

Hinson, J. T., Chopra, A., Nafissi, N., Polacheck, W. J., Benson, C. C., Swist, S., Gorham, J., Yang, L., Schafer, S., Sheng, C. C., Haghighi, A., Homsy, J., Hubner, N., Church, G., Cook, S. A., Linke, W. A., Chen, C. S., Seidman, J. G., & Seidman, C. E. (2015). HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science (New York, N.Y.), 349(6251), 982–986. https://doi.org/10.1126/science.aaa5458

Ho, C. Y., Day, S. M., Ashley, E. A., Michels, M., Pereira, A. C., Jacoby, D., Cirino, A. L., Fox, J. C., Lakdawala, N. K., Ware, J. S., Caleshu, C. A., Helms, A. S., Colan, S. D., Girolami, F., Cecchi, F., Seidman, C. E., Sajeev, G., Signorovitch, J., Green, E. M., & Olivotto, I. (2018). Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation, 138(14), 1387–1398. https://doi.org/10.1161/CIRCULATIONAHA.117.033200

Homburger, J. R., Green, E. M., Caleshu, C., Sunitha, M. S., Taylor, R. E., Ruppel, K. M., Metpally, R. P., Colan, S. D., Michels, M., Day, S. M., Olivotto, I., Bustamante, C. D., Dewey, F. E., Ho, C. Y., Spudich, J. A., & Ashley, E. A. (2016). Multidimensional structure-function relationships in human ß-cardiac myosin from population-scale genetic variation. Proceedings of the National Academy of Sciences of the United States of America, 113(24), 6701–6706. https://doi.org/10.1073/pnas.1606950113

Ostrominski, J. W., Thierer, J., Claggett, B. L., Miao, Z. M., Desai, A. S., Jhund, P. S., Kosiborod, M. N., Lam, C. S. P., Inzucchi, S. E., Martinez, F. A., de Boer, R. A., Hernandez, A. F., Shah, S. J., Petersson, M., Langkilde, A. M., McMurray, J. J. V., Solomon, S. D., & Vaduganathan, M. (2023). Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC. Heart failure, 11(11), 1491–1503. https://doi.org/10.1016/j.jchf.2023.05.015

Reuter, U., Goadsby, P. J., Lanteri-Minet, M., Wen, S., Hours-Zesiger, P., Ferrari, M. D., & Klatt, J. (2018). Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet (London, England), 392(10161), 2280–2287. https://doi.org/10.1016/S0140-6736(18)32534-0

Seo, J., Kim, M., Hong, G. R., Kim, D. S., Son, J. W., Cho, I. J., Shim, C. Y., Chang, H. J., Ha, J. W., & Chung, N. (2016). Fabry disease in patients with hypertrophic cardiomyopathy: a practical approach to diagnosis. Journal of human genetics, 61(9), 775–780. https://doi.org/10.1038/jhg.2016.52

Spudich J. A. (2024). One must reconstitute the functions of interest from purified proteins. Frontiers in physiology, 15, 1390186. https://doi.org/10.3389/fphys.2024.1390186

Wikipedia Contributors. (2019, October 19). Shotgun sequencing. Wikipedia; Wikimedia Foundation. https://en.wikipedia.org/wiki/Shotgun_sequencing

Yi, J. S., Perla, S., & Bennett, A. M. (2023). An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies. Cardiovascular drugs and therapy, 37(6), 1193–1204. https://doi.org/10.1007/s10557-022-07324-0

Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., De Winter, T., Elliott, P. M., Flather, M., Garcia-Pavia, P., Haugaa, K. H., Ingles, J., Jurcut, R. O., Klaassen, S., Limongelli, G., Loeys, B., … ESC Scientific Document Group (2023). 2023 ESC Guidelines for the management of cardiomyopathies. European heart journal, 44(37), 3503–3626. https://doi.org/10.1093/eurheartj/ehad194

Farrant, J. P., Schmitt, M., Reid, A. B., Garratt, C. J., Newman, W. G., Malhotra, A., Beynon, R., Mahmod, M., Raman, B., Cooper, R. M., Dawson, D., Green, T., Prasad, S. K., Singh, A., Dodd, S., Watkins, H., Neubauer, S., & Miller, C. A. (2025). Considerations for drug trials in hypertrophic cardiomyopathy. ESC heart failure, 12(2), 1095–1112. https://doi.org/10.1002/ehf2.15138

Kawana, M., Spudich, J. A., & Ruppel, K. M. (2022). Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies. Frontiers in physiology, 13, 975076. https://doi.org/10.3389/fphys.2022.975076

Klues, H. G., Maron, B. J., Dollar, A. L., & Roberts, W. C. (1992). Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation, 85(5), 1651–1660. https://doi.org/10.1161/01.cir.85.5.1651

Maron, B. J., Shirani, J., Poliac, L. C., Mathenge, R., Roberts, W. C., & Mueller, F. O. (1996). Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA, 276(3), 199–204.

Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., Joglar, J. A., Khan, S. S., Kim, J. J., Kittleson, M. M., Krittanawong, C., Martinez, M. W., Mital, S., Naidu, S. S., Saberi, S., Semsarian, C., Peer Review Committee Members (2024). 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 149(23), e1239–e1311. https://doi.org/10.1161/CIR.0000000000001250

For CME general questions, please contact 
     Email: [email protected]

Mitigation of Relevant Financial Relationships

Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the table below. All of the relevant financial relationships listed for these individuals have been mitigated.

This CME Activity is supported by an educational grant from Bristol Myers Squibb.